---
title: "Antidepressant Side-Effects: Cardiometabolic & Physiological Guide"
description: "How common antidepressants differ on weight, blood pressure, heart rate, cholesterol, glucose, liver enzymes, electrolytes, and QTc — plus monitoring and safer choices by risk profile."
category: "Mental Health"
publishDate: "2025-10-23"
tags: ["antidepressants", "side-effects", "cardiometabolic", "metabolic-health"]
draft: false
---

## Intro

Antidepressants can meaningfully affect **weight**, **blood pressure (BP)**, **heart rate (HR)**, **lipids**, **glucose**, and **liver enzymes**. These effects vary substantially by drug and class, and matter most for people with **obesity, hypertension, diabetes risk, dyslipidemia, or cardiovascular disease**.

Short-term randomized trials consistently show **wide physiological spreads between agents**, even when antidepressant efficacy is similar.

---

## Key Points

- Short-term trials show approximately **4 kg spread in weight change**, **~20 bpm spread in heart rate**, and **~11 mmHg spread in systolic BP** across antidepressants  
- **SNRIs** (venlafaxine, desvenlafaxine, duloxetine, levomilnacipran) increase **BP** and **cholesterol**; duloxetine also shows small increases in **glucose** and **AST/ALT**  
- **TCAs** (amitriptyline, imipramine, maprotiline) increase **heart rate**, **blood pressure**, and **weight**  
- **Agomelatine**, **fluoxetine**, and **bupropion** show more favorable **short-term weight profiles**  
- QTc prolongation and hyponatremia are uncommon in trials but rise in **older, multimorbid, real-world populations**

---

## Evidence Summary (Network Meta-Analysis)

**Source:** Pillinger et al., *The Lancet* (2025)  
**Data:** 151 randomized controlled trials · ~58,500 participants · 30 antidepressants

**Key findings:**

- SNRIs increase blood pressure and cholesterol  
- Duloxetine shows small increases in glucose and liver enzymes  
- TCAs increase heart rate, blood pressure, and weight  
- Agomelatine, fluoxetine, and bupropion show less weight gain or modest weight loss short-term  
- Short-term trials show minimal QTc and sodium signal, likely underestimating real-world risk

---

## Options by Clinical Profile

### Metabolic risk (obesity, type 2 diabetes, dyslipidemia)

Prefer:
- Agomelatine
- Fluoxetine
- Bupropion

Avoid when possible:
- Mirtazapine
- TCAs
- High-dose SNRIs

---

### Hypertension or cardiovascular disease

Avoid or monitor closely:
- Venlafaxine
- Desvenlafaxine
- Duloxetine
- Levomilnacipran
- TCAs

---

### Weight-gain sensitivity

Higher risk:
- Mirtazapine
- Amitriptyline
- Maprotiline

Lower risk:
- Bupropion
- Fluoxetine
- Agomelatine

---

### Older adults or polypharmacy

- Start low and titrate slowly  
- Consider baseline and follow-up **sodium** and **QTc** monitoring

---

## Monitoring (First 8–12 Weeks)

- **Baseline → Week 4 → Week 8:** weight, waist circumference, BP, HR  
- **Labs when indicated:**
  - Fasting lipids and glucose (especially with SNRIs)
  - Liver enzymes (duloxetine, desvenlafaxine, levomilnacipran)
- **Electrolytes (Na⁺)** and **ECG (QTc)** for older adults or those on diuretics or QT-prolonging drugs

---

## Generic → Trade Names

**SSRIs:**  
Fluoxetine (Prozac), Sertraline (Zoloft), Paroxetine (Paxil),  
Citalopram (Celexa), Escitalopram (Lexapro), Fluvoxamine (Luvox)

**SNRIs:**  
Venlafaxine (Effexor), Desvenlafaxine (Pristiq),  
Duloxetine (Cymbalta), Levomilnacipran (Fetzima)

**Atypical:**  
Bupropion (Wellbutrin), Agomelatine (Valdoxan), Mirtazapine (Remeron)

**TCAs:**  
Amitriptyline (Elavil), Nortriptyline (Pamelor),  
Imipramine (Tofranil), Doxepin (Sinequan), Maprotiline (Ludiomil)

---

## FAQ

**Do SSRIs behave the same physiologically?**  
No. Paroxetine shows more lipid and weight effects; fluoxetine, sertraline, and escitalopram are more neutral short-term.

**If weight falls early, will it stay down?**  
Not reliably. Longer observational cohorts often show net weight gain with chronic use.

**Are QTc or sodium problems common?**  
Not in short-term trials, but registry data in older or multimorbid patients shows increased risk. Monitor when indicated.

---

## Further Reading

- Pillinger T et al. *The Lancet* (2025). doi:10.1016/S0140-6736(25)01293-0  
- NICE. *Depression in adults: treatment and management.*

<script type="application/ld+json">
{JSON.stringify({
  "@context": "https://schema.org",
  "@type": "MedicalWebPage",
  "name": "Antidepressant Side-Effects: Cardiometabolic & Physiological Guide",
  "description": "Comparative cardiometabolic and physiological side-effects of antidepressants with monitoring guidance.",
  "datePublished": "2025-10-23",
  "dateModified": "2025-10-23",
  "breadcrumb": {
    "@type": "BreadcrumbList",
    "itemListElement": [
      { "@type": "ListItem", "position": 1, "name": "Guides", "item": "https://patientguide.io/guides" },
      { "@type": "ListItem", "position": 2, "name": "Mental Health", "item": "https://patientguide.io/guides/category/mental-health/" },
      { "@type": "ListItem", "position": 3, "name": "Antidepressant Side-Effects", "item": "https://patientguide.io/guides/antidepressant-side-effects/" }
    ]
  }
})}
</script>
